Supplementary Figure S4 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors

Key Points

• MAIN FINDING: Azenosertib demonstrates significant antitumor activity across various solid tumors.
• KEY EVIDENCE: The impact of azenosertib on hematologic populations was assessed in immune competent mouse models.
• APPROACH: Testing involved immune competent mouse models to analyze azenosertib's effects on tumor growth.
• SIGNIFICANCE: These findings highlight the importance of azenosertib as a potential treatment option for solid tumors.